Manipulating selectivity through gatekeeper interactions: Inhibition of EGFR and its T790M mutant

被引：0

作者：

Hanan, Emily ^{[1
]}

Bryan, Marian ^{[1
]}

Burdick, Daniel ^{[1
]}

Chan, Bryan ^{[1
]}

Chen, Yuan ^{[1
]}

Eigenbrot, Charles ^{[1
]}

Heald, Robert ^{[2
]}

Heffron, Timothy ^{[1
]}

La, Hank ^{[1
]}

Purkey, Hans ^{[1
]}

Schaefer, Gabriele ^{[1
]}

Schmidt, Stephen ^{[1
]}

Seward, Eileen ^{[2
]}

Sideris, Steve ^{[1
]}

Wang, Shumei ^{[1
]}

Yu, Christine ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

[2] Discovery Charles River, Harlow, Essex, England

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

620

引用

页数：1

共 50 条

[21] Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Janjigian, Yelena Y.
Smit, Egbert F.
Groen, Harry J. M.
Horn, Leora
Gettinger, Scott
Camidge, D. Ross
Riely, Gregory J.
Wang, Bushi
Fu, Yali
Chand, Vikram K.
Miller, Vincent A.
Pao, William
CANCER DISCOVERY, 2014, 4 (09) : 1036 - 1045
[22] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
Hwang, Ji An
Choi, Chang-Min
Lee, Jae Cheol
EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[23] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
Mohorcic, K.
Janzic, A.
Janzic, U.
Rot, M.
Kern, I.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
[24] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
Hoogenboom, Niels
Demont, Dennis
de Zwart, Edwin
Verkaik, Saskia
Emmelot, Maaike
van de Kar, Bas
Kaptein, Allard
Barf, Tjeerd
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
[25] Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer
Hata, Akito
Katakami, Nobuyuki
Kaji, Reiko
Fujita, Shiro
Imai, Yukihiro
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : E27 - E29
[26] Deciphering the Selective Targeting of Noncovalent, Wild Type-sparing, and ATP-competitive Tyrosine Kinase Inhibitors to EGFR T790M Gatekeeper Mutant
Meng, Shu
Cheng, Jin
Wu, Hongyan
Wang, Jing
JOURNAL OF COMPUTATIONAL BIOPHYSICS AND CHEMISTRY, 2025,
[27] Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Zhao, S.
Jiang, T.
Li, X.
Zhao, C.
Su, C.
Ren, S.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S410 - S410
[28] Is T790M Mutation A "Regulator" for EGFR Signal Pathway Not an Oncogene?
Wang, Zheng
Liu, Dongge
Shi, Yuankai
Han, Xiaohong
Tong, Hongfeng
Wu, Qingjun
Zhang, Jianguang
Wang, Tianyang
Cram, David
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S487 - S487
[29] Reducing proteome reactivity of irreversible inhibitors of EGFR T790M
Kath, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[30] HIGH PREVALENCE OF GERMLINE EGFR T790M MUTATIONS IN LUNG CANCER PATIENTS WHOSE TUMORS HARBOR BASELINE T790M
Oxnard, Geoffrey R.
Arcila, Maria E.
Kris, Mark G.
Ladanyi, Marc
Miller, Vincent A.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S510 - S511

← 1 2 3 4 5 →